2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wu, Sherry Y ^a   Yang, Xianbin ^b   Gharpure, Kshipra M ^a   Hatakeyama, Hiroto ^a   Egli, Martin ^c   McGuire, Michael H ^a   Nagaraja, Archana S ^a   Miyake, Takahito M ^a   Rupaimoole, Rajesha ^a   Pecot, Chad V ^a   Taylor, Morgan ^a   Pradeep, Sunila ^a   Sierant, Malgorzata ^d   Rodriguez Aguayo, Cristian ^a   Choi, Hyun J ^a   Previs, Rebecca A ^a   Armaiz Pena, Guillermo N ^a   Huang, Li ^a   Martinez, Carlos ^e   Hassell, Tom ^e   Ivan, Cristina ^a   Sehgal, Vasudha ^a   Singhania, Richa ^f,g   Han, Hee Dong ^a,h   Su, Chang ^a   Kim, Ji Hoon ^a,i   Dalton, Heather J ^a   Kovvali, Chandra ^a   Keyomarsi, Khandan ^a   McMillan, Nigel A J ^f,j   Overwijk, Willem W ^a   Liu, Jinsong ^a   Lee, Ju Seog ^a   Baggerly, Keith A ^a   Lopez Berestein, Gabriel ^a   Ram, Prahlad T ^a   Nawrot, Barbara ^d   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AM Biotechnologies   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

^e Sigma Life Science   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h Konkuk University School of Medicine   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j GRIFFITH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; 2' O METHYL; ALPHA INTERFERON; CASPASE 3; EPHRIN RECEPTOR A2; GRAM DOMAIN CONTAINING 1B; MESSENGER RNA; METHYL GROUP; NANOCARRIER; PACLITAXEL; PHOSPHORODITHIOIC ACID; PHOSPHOROTHIOIC ACID; PROTEIN; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PHOSPHATE;

DISEASE CONTROL; DISEASE TREATMENT; PROTEIN; RNA; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONEAL CAVITY; POLYMERASE CHAIN REACTION; PROTEIN TARGETING; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; RNA STRUCTURE; SINGLE DRUG DOSE; THERMOSTABILITY; ANIMAL; CHEMISTRY; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; PHOSPHATES; RNA, SMALL INTERFERING; RNA-INDUCED SILENCING COMPLEX; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896259886     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4459     Document Type: Article

References (51)

1. Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3, 406-417 (2013).
2. Davis, M. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
3. Valentino, J. et al. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. Surgery 152, 277-285 (2012).
4. Wu, S. et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther. 18, 14-22 (2011).
5. Wu, S. & McMillan, N. Lipidic systems for in vivo siRNA delivery. AAPS J. 11, 639-652 (2009).
6. Pecot, C., Calin, G., Coleman, R., Lopez-Berestein, G. & Sood, A. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59-67 (2011).
7. Choung, S., Kim, Y., Kim, S., Park, H. & Choi, Y. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342, 919-927 (2006). (Pubitemid 43320485)
8. Kenski, D. et al. siRNA-optimized modifications for enhanced in vivo activity. Mol. Ther. Nucleic Acids 1, e5 (2012).
9. Volkov, A. et al. Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides 19, 191-202 (2009).
10. Behlke, M. A. Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-670 (2006).
11. Stein, D., Foster, E., Huang, S. B., Weller, D. & Summerton, J. A specificity comparison of four antisense types: morpholino, 20-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7, 151-157 (1997). (Pubitemid 27323073)
12. Stein, C. A. Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. Chem. Biol. 3, 319-323 (1996). (Pubitemid 126663330)
13. Raal, F. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
14. Prakash, T. et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247-4253 (2005). (Pubitemid 40884928)
15. Yang, X. et al. Gene silencing activity of siRNA molecules containing phosphorodithioate substitutions. ACS Chem. Biol. 7, 1214-1220 (2012).
16. Wiesler, W. T. & Caruthers, M. H. Synthesis of pohosphorodithioate DNA via sulfur-linked, base-labile protecting groups. J. Org. Chem. 61, 4272-4281 (1996). (Pubitemid 26236913)
17. Marshall, W. S. & Caruthers, M. H. Phosphorodithioate DNA as a potential therapeutic drug. Science 259, 1564-1570 (1993). (Pubitemid 23114637)
18. Khairuddin, N. et al. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumours in vivo. Immunol. Cell Biol. 90, 187-196 (2012).
19. Yin, Y. et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo. Int. J. Oncol. 42, 253-260 (2013).
20. Elmén, J. et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439-447 (2005). (Pubitemid 40276964)
21. Landen, C. J. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
22. Bramsen, J. et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37, 2867-2881 (2009).
23. Sipa, K. et al. Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA 13, 1301-1316 (2007). (Pubitemid 47080475)
24. Rana, T. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8, 23-36 (2007). (Pubitemid 46012012)
25. Chiu, Y. & Rana, T. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-1048 (2003). (Pubitemid 37093614)
26. Eckstein, F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10, 117-121 (2000). (Pubitemid 30255596)
27. Rand, T., Ginalski, K., Grishin, N. & Wang, X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl Acad. Sci. USA 101, 14385-14389 (2004). (Pubitemid 39346758)
28. Jackson, A. et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197-1205 (2006). (Pubitemid 43990545)
29. Ma, J., Ye, K. & Patel, D. Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429, 318-322 (2004). (Pubitemid 38684819)
30. Lubini, P., Zürcher, W. & Egli, M. Crystal structure of an oligodeoxynucleotide duplex containing 2'-O-methylated adenosines. Chem. Biol. 1, 39-45 (1994).
31. Abdelmawla, S. et al. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol. Ther. 19, 1312-1322 (2011).
32. Bowen, N. et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med. Genomics 2, 71 (2009).
33. Bridgewater, J. et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin. Oncol. 17, 501-508 (1999). (Pubitemid 29075234)
34. Chin, L., Hahn, W., Getz, G. & Meyerson, M. Making sense of cancer genomic data. Genes Dev. 25, 534-555 (2011).
35. Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322-333 (2006). (Pubitemid 43160055)
36. Kraynack, B. & Baker, B. Small interfering RNAs containing full 20-Omethylribonucleotide- modified sense strands display Argonaute2/eIF2C2- dependent activity. RNA 12, 163-176 (2006). (Pubitemid 43037463)
37. Kubo, T. et al. SiRNAs conjugated with aromatic compounds induce RISCmediated antisense strand selection and strong gene-silencing activity. Biochem. Biophys. Res. Commun. 426, 571-577 (2012).
38. Vivas-Mejia, P. et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin. Cancer Res. 17, 3716-3726 (2011).
39. Yang, X., Hodge, R., Luxon, B., Shope, R. & Gorenstein, D. Separation of synthetic oligonucleotide dithioates from monothiophosphate impurities by anion-exchange chromatography on a mono-q column. Anal. Biochem. 306, 92-99 (2002). (Pubitemid 34722021)
40. Pecot, C. et al. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 4, 2427 (2013).
41. Cheng, A. et al. Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. Oligonucleotides 19, 203-208 (2009).
42. Le, M. et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet. 7, e1002242 (2011).
43. Pei, Y. et al. Quantitative evaluation of siRNA delivery in vivo. RNA 16, 2553-2563 (2010).
44. 2immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PloS One 4, e7192 (2009).
45. Hatakeyama, H., Akita, H., Maruyama, K., Suhara, T. & Harashima, H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm. 281, 25-33 (2004). (Pubitemid 39024260)
46. Armaiz-Pena, G. et al. Src activation by b-adrenoreceptors is a key switch for tumour metastasis. Nat. Commun. 4, 1403 (2013).
47. Komurov, K., White, M. & Ram, P. Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data. PLoS Comput. Biol. 6, e1000889 (2010).
48. Lamendola, D., Duan, Z., Yusuf, R. & Seiden, M. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 63, 2200-2205 (2003). (Pubitemid 36538627)
49. Ahmed, A. et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18, 109-121 (2010).
50. Merritt, W. et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. New Engl. J. Med. 359, 2641-2650 (2008).
51. Pettersen, E. et al. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comp. Chem. 25, 1605-1612 (2004).